The earnings call revealed a mixed picture with notable achievements in international growth, profitability improvements, and strategic acquisitions, while facing challenges in North American revenue and COVID-related declines. The company's cost-saving initiatives and improved margins are positive indicators, but the downward revision of COVID revenue guidance and the challenges in China suggest caution.

Company Guidance -

Q3 2025

During the QuidelOrtho Second Quarter 2025 Financial Results Conference Call, the company provided several key metrics and guidance. Total revenue for Q2 was $614 million, with organic constant currency growth of 5% in the Labs business and 3% in Immunohematology. The respiratory business saw a $2 million revenue decline, excluding COVID impacts. Regionally, North America revenue declined by 12%, while growth was observed in Latin America (14%), Japan (6%), and Asia Pacific (6%). China experienced 2% growth despite tariff-related challenges, with expectations for mid-single-digit growth for the remainder of 2025. Adjusted EBITDA margin improved by 330 basis points, and adjusted diluted EPS increased compared to the prior year. The company expects full-year 2025 total reported revenue between $2.6 billion and $2.81 billion, maintaining previous guidance for adjusted EBITDA of $575 million to $615 million, reflecting a 22% margin. Additionally, potential tariff headwinds are now estimated at $20-$25 million, down from an earlier range of $30-$40 million, with mitigation efforts expected to offset these impacts.

Solid Q2 Revenue and Growth in Key Segments

Total revenue of $614 million grew 1% year-over-year, excluding COVID and Donor Screening. Labs and Immunohematology business units reported organic constant currency growth of 5% and 3%, respectively.

Strong International Performance

EMEA growth was up 3% in Q2 and 6% year-to-date. Other regions grew 10% in Q2, with 14% growth in Latin America and 6% growth in Japan and Asia Pacific.

Improved Profitability

Adjusted EBITDA margin improved by 330 basis points. Adjusted diluted EPS showed a meaningful improvement compared to the prior year period.

Significant Cost Savings and Efficiency

The company achieved $30 million to $50 million in incremental cost savings, with a focus on indirect procurement and staffing reductions.

LEX Diagnostics Acquisition and Molecular Strategy

The acquisition of LEX Diagnostics is expected to enhance molecular diagnostics capabilities with an innovative platform that can deliver results in minutes.

QuidelOrtho (QDEL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

QDEL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	0.52 / -	0.85	―	―	―
Aug 05, 2025	2025 (Q2)	<0.01 / 0.12	-0.07	271.43% (+0.19)
May 07, 2025	2025 (Q1)	0.59 / 0.74	0.44	68.18% (+0.30)
Feb 12, 2025	2024 (Q4)	0.59 / 0.63	1.17	-46.15% (-0.54)
Nov 07, 2024	2024 (Q3)	0.27 / 0.85	0.9	-5.56% (-0.05)
Jul 31, 2024	2024 (Q2)	-0.23 / -0.07	0.26	-126.92% (-0.33)
May 08, 2024	2024 (Q1)	0.39 / 0.44	1.8	-75.56% (-1.36)
Feb 13, 2024	2023 (Q4)	2.04 / 1.17	1.76	-33.52% (-0.59)
Nov 01, 2023	2023 (Q3)	0.60 / 0.90	1.85	-51.35% (-0.95)
Aug 08, 2023	2023 (Q2)	0.28 / 0.26	2.34	-88.89% (-2.08)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

QDEL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$23.68	$23.44	-1.01%
May 07, 2025	$25.85	$36.46	+41.04%
Feb 12, 2025	$39.94	$41.65	+4.28%
Nov 07, 2024	$38.85	$43.75	+12.61%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.